Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

220.31 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗

November 14, 2025

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

November 14, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders

November 14, 2025

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral ↗

October 09, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗

November 14, 2025

With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.

Via Stocktwits

Topics Intellectual Property

Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

November 14, 2025

Via Benzinga

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight? ↗

November 14, 2025

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

Via Benzinga

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

October 27, 2025

Via Benzinga

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' ↗

October 10, 2025

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.

Via Benzinga

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage ↗

October 10, 2025

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan...

Via Benzinga

Why Cidara Therapeutics Stock Crushed It Today ↗

October 09, 2025

The company earned an important fast-track review designation for a pipeline medication.

Via The Motley Fool

Cidara Shares Are Trading Higher Friday: What's Going On? ↗

October 03, 2025

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.

Via Benzinga

Why Cidara Therapeutics Was Such a Healthy Stock Today ↗

September 26, 2025

The company could have quite a winner on its hands with its most advanced pipeline drug.

Via The Motley Fool

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗

September 24, 2025

Via Stocktwits

Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High ↗

September 24, 2025

The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.

Via Investor's Business Daily

Topics Intellectual Property

Cidara (CDTX) Q2 Cash Surges 163% ↗

August 07, 2025

Via The Motley Fool

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains ↗

June 30, 2025

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

Via MarketBeat

FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 25, 2025

Via Benzinga

Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

June 25, 2025

Via Benzinga

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 24, 2025

Via Benzinga

Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering ↗

June 23, 2025

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Via Stocktwits

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial ↗

June 23, 2025

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Crude Oil Falls 1%; US Services PMI Declines In June ↗

June 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 23, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.